medline.ch Gastroenterologie Magen-Darm Entzündliche Darmerkrankungen

	Redefining Neutrophil Function in Inflammatory Bowel Disease: From Tissue Injury to Immune Resolution. Mol Biol Rep Khademi M, Kazemifard N, Ghavami SB, Farmani M, Shahrokh S. PMID: 42429844 [PubMed - indexed for MEDLINE]
	Sialidase inhibitor modulates gut microbiota and enhances mucosal protection in the treatment of ulcerative colitis. mSystems Zhao Y, Chen L, Li C, Xu Y, Huang J, Chen S, Yu Z, Liu X. PMID: 42429666 [PubMed - as supplied by publisher]
	Comparative efficacy of advanced therapies in biological-exposed ulcerative colitis - a network meta-analysis of randomized trials. Eur J Gastroenterol Hepatol Giri S, Kulkarni A, Harindranath S, Malakar S, Jena A, Joshi H, Nath P. PMID: 42429193 [PubMed - as supplied by publisher]
	Short-chain fatty acids in ulcerative colitis: integrating metabolic fate, dynamic biomarkers, and precision delivery. Front Nutr Ying Z, Tian M, Huang X, Ping G, Jiang C. PMID: 42428604 [PubMed]
	Systematic review and network meta-analysis of integrated traditional Chinese and conventional medicine for ulcerative colitis. Front Pharmacol Li X, Sha Z. PMID: 42428503 [PubMed]
	Efficacy and safety of ustekinumab in Asian patients with moderately to severely active Crohn's disease: a small subpopulation analysis of UNITI/IM-UNITI long-term extension through 5 years. Intest Res Ye BD, Sugimoto K, Cheon JH, Gasink C, Imai Y, Wahking B, Zhuo J, Kawamura S, Hibi T. PMID: 42427284 [PubMed - as supplied by publisher]
	Efficacy and safety of ozanimod in Japanese patients with moderately to severely active ulcerative colitis naive to immunomodulators or advanced therapies: post hoc analysis of the phase 2/3 J-True North study. Intest Res Hisamatsu T, Fujii T, Nakase H, Matsuoka K, Saruta M, Kobayashi T, Inoue S, Toriyama K, Wang D, Uchikawa Y, Fujimoto G, Hibi T. PMID: 42427283 [PubMed - as supplied by publisher]
	Real-World Effectiveness, Safety and Quality of Life With Ustekinumab for the Treatment of Crohn's Disease: Results of the UK Ustekinumab Real World Evidence Study (UndieS) Study Group. Aliment Pharmacol Ther Young D, Booker C, Samaan M, Kok K, Donovan F, Hart A, Batchelor J, Limdi J, Bodger K, Cummings JRF, UndieS study group. PMID: 42426976 [PubMed - as supplied by publisher]
	Comment on "Dose-dependent efficacy and safety of Filgotinib in moderate to severe Crohn's disease: a grade-assessed systematic review and meta-analysis of randomized controlled trials". Eur J Clin Pharmacol Laskar TT, Borah S, Arora M. PMID: 42426347 [PubMed - in process]
	Small bowel obstruction secondary to Strongyloides stercoralis: a rare cause and mimic of inflammatory bowel disease. BMJ Case Rep Malkopoulos A, Subhaharan D, Kamal S, Haig A. PMID: 42425604 [PubMed - indexed for MEDLINE]
	Two trials with two different answers: potential for Bayesian re-analysis in a Crohn's disease clinical trial. Gastroenterology César da Silva B, Noor NM. PMID: 42425310 [PubMed - as supplied by publisher]
	Rising Burden and Clinical Impact of Metabolic Syndrome in Inflammatory Bowel Disease: A Real-World CohortÂ Study. United European Gastroenterol J Tariq R, Parmar K, Desai M, Sterling RK, Sanyal AJ. PMID: 42424118 [PubMed - indexed for MEDLINE]
	Integrative single-cell transcriptomics and mendelian randomization identifies BTN3A2 as a shared protective factor in BehÃ§et's disease and inflammatory bowel disease. Front Immunol Dai Q, Wu Y, Geng W, Li M, Zhang W, Lai Y, Zhang P, Zhou C, Wang Y, Cao Q, Luo X, Lai Y, Huang C, Yang P. PMID: 42421947 [PubMed - indexed for MEDLINE]
	Comparison of six nutritional screening tools for identifying BMIâ€‘defined malnutrition in patients with Crohn's disease: a crossâ€‘sectional study. BMC Gastroenterol Yu Z, Duan R, Liu Q, Mei W, Chen D, Pan T, Chen Y, Kong F, Ding C. PMID: 42420858 [PubMed - as supplied by publisher]
	Off-label upadacitinib 60Â mg daily in the rescue of refractory ulcerative colitis: an open-labeled cohort study. J Crohns Colitis Gu B, Kariyawasam V, Leong RW. PMID: 42418656 [PubMed - in process]
	Timing of biologic prophylaxis and postoperative recurrence in Crohn's disease: A real-life cohort study using propensity score weighting. Inflamm Bowel Dis Del Gaudio A, Di Vincenzo F, Cuccia G, Coppola G, Laterza L, Sacchetti F, Caprino P, Sofo L, Dragoni G, Foscarini E, Profeta F, Schiavoni E, Napolitano D, Gasbarrini A, Pugliese D, Papa A, Lopetuso LR, Scaldaferri F. PMID: 42418506 [PubMed - as supplied by publisher]
	Harmaline and the gut-brain-immune axis: a novel therapeutic avenue in neuroinflammation and ulcerative colitis. Inflammopharmacology Giri M, Arya S, Grover M, Yadav D, Chatterjee S, Rath SK. PMID: 42417936 [PubMed - as supplied by publisher]
	Multi-stakeholder Delphi consensus on future care for inflammatory bowel disease in Belgium. Acta Gastroenterol Belg Taelman T, Deprez N, King J, Baert F, Cremer A, Ferrante M, Sabino J, Reenaers C, Arijs I, Bossuyt P. PMID: 42417641 [PubMed - indexed for MEDLINE]
	Outcomes of autologous hematopoietic stem cell transplantation in patients with refractory Crohn's disease: a single-center retrospective case series. Acta Gastroenterol Belg Geebelen G, Van Besien A, Van Ham J, D'Hooghe AT, Ferrante M, Sabino J, Verstockt B, Dierickx D, Vermeire S. PMID: 42417636 [PubMed - indexed for MEDLINE]
	From theory to practice: a Belgian consensus on minimal monitoring strategies for patients with IBD treated with advanced therapies. Acta Gastroenterol Belg Truyens M, Cremer A, Jauregui-Amezaga A, Verstockt B, Sabino J, Pouillon L, Bird Group T, Lobatón T. PMID: 42417635 [PubMed - indexed for MEDLINE]

Artikel 1 - 20 / 58218

Seite 1 von 2911



		Zeitfenster

	Mediscope AG E-mail: info@mediscope.ch
	Disclaimer \| Datenschutzerklärung / Privacy Policy \| Werbung